TAC1 and Cognitive impairment: CB1 receptors are predominantly expressed in the central nervous system (CNS); their activation leads to inhibition of neurotransmitter release, particularly glutamate and substance P, thus reducing nociceptive signal transmission; and their activation is associated with centrally mediated antinociceptive effects, but also with psychotropic side effects (e.g., euphoria, cognitive impairment).